Craft

Pernix Therapeutics

Stock Price

$887.8

2020-04-29

Market Capitalization

$3 M

2019-03-04

Revenue

$146.1 M

FY, 2017

Pernix Therapeutics Summary

Company Summary

Overview
Pernix Therapeutics is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products primarily for the pediatric market. The company’s pediatric products, designed to improve the health and well-being of children, are focused in the specific areas of allergy, upper respiratory, including nasal, chest congestion and cough, antibiotics and dermatology, including head lice, and contact dermatitis.
Type
Public
Status
Closed
HQ
Morristown, NJ, US | view all locations
Website
http://www.pernixtx.com
Cybersecurity rating
Sectors

Key People

  • Kenneth R. Piña

    Kenneth R. Piña, Senior Vice President, Chief Legal & Compliance Officer and Corporate Secretary

    • Angus Smith

      Angus Smith, Senior Vice President, Chief Business Officer and Principal Financial Officer

      • Christopher J. Bordiuk

        Christopher J. Bordiuk, Vice President, Human Resources

        • George P. Jones

          George P. Jones, Vice President of Sales and Marketing

          LocationsView all

          1 location detected

          • Morristown, NJ HQ

            United States

            Morristown, NJ 07960, USA

          Pernix Therapeutics Financials

          Summary Financials

          Revenue (Q3, 2018)
          $37.2M
          Gross profit (Q3, 2018)
          $25.3M
          Net income (Q3, 2018)
          ($11.8M)
          Cash (Q3, 2018)
          $24.5M
          EBIT (Q3, 2018)
          ($10.5M)
          Enterprise value
          $300.9M

          Footer menu